人工智能驱动的帕金森病精确诊断和治疗:综合性审查和实验分析
1Office of the DVC for Digital Transformation, Tshwane University of Technology, Pretoria, South Africa.
Frontiers in aging neuroscience
|August 12, 2025
概括
人工智能 (AI) 显著改善了帕金森病 (PD) 诊断,在早期检测中达到94.2%的准确性. 这种AI方法增强了PD患者的个性化治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 医疗信息学 医疗信息学
- 人工智能的人工智能
背景情况:
- 帕金森病 (PD) 是一种广泛的神经退行性疾病,在全球影响超过1000万.
- 目前的诊断方法依赖于主观的临床评估,往往导致延迟或不准确的诊断.
- 人工智能 (AI) 为准确的PD诊断和个性化的治疗提供了一个变革性的机会.
研究的目的:
- 在帕金森病的诊断和治疗中对人工智能应用进行全面的审查.
- 评估现有的PD人工智能方法.
- 展示PD新型多式联络AI诊断框架的实验结果.
主要方法:
- 使用PubMed,IEEE Xplore和Web of Science (2018-2024) 进行了一次系统的文献审查.
- 开发了一个混合机器学习模型,集成深度学习,计算机视觉和自然语言处理.
- 该模型利用运动症状分析,语音模式识别和步态分析进行PD评估.
主要成果:
- 系统性审查确定了127项研究,显示AI驱动的PD诊断准确率在78%至96%之间.
- 开发的多式联络人工智能框架在早期PD检测中实现了94.2%的准确性.
- 人工智能方法在识别微妙的运动波动和预测治疗反应方面表现出色.
结论:
- 人工智能具有巨大的潜力,可以彻底改变PD诊断和个性化治疗策略.
- 整合多式联网数据和先进的人工智能,可实现更早的检测,更准确的监测和优化治疗.
- 未来的研究应该优先考虑大规模的临床验证和医疗保健系统实施框架.
相关概念视频
01:24Parkinson's Disease: Treatment
380
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
380
01:15Parkinson's Disease: Overview
704
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
704
01:22Alzheimer's Disease: Treatment
261
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
261
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
35
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
35